LU91610I2 - Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé) - Google Patents

Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)

Info

Publication number
LU91610I2
LU91610I2 LU91610C LU91610C LU91610I2 LU 91610 I2 LU91610 I2 LU 91610I2 LU 91610 C LU91610 C LU 91610C LU 91610 C LU91610 C LU 91610C LU 91610 I2 LU91610 I2 LU 91610I2
Authority
LU
Luxembourg
Prior art keywords
protein
influenzae
synflorix
adsorbed
pharmaceutically acceptable
Prior art date
Application number
LU91610C
Other languages
English (en)
Original Assignee
Forsgren Arne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20379641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91610(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Forsgren Arne filed Critical Forsgren Arne
Publication of LU91610I2 publication Critical patent/LU91610I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1242—Gram-negative bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/11—Automated chemical analysis
    • Y10T436/115831—Condition or time responsive
    • Y10T436/116664—Condition or time responsive with automated titrator

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU91610C 1990-05-31 2009-09-24 Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé) LU91610I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9001949A SE466259B (sv) 1990-05-31 1990-05-31 Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
PCT/SE1991/000129 WO1991018926A1 (fr) 1990-05-31 1991-02-21 PROTEINE D - PROTEINE FIXATRICE D'IgD, DE HAEMOPHILUS INFLUENZAE

Publications (1)

Publication Number Publication Date
LU91610I2 true LU91610I2 (fr) 2009-11-24

Family

ID=20379641

Family Applications (2)

Application Number Title Priority Date Filing Date
LU91610C LU91610I2 (fr) 1990-05-31 2009-09-24 Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)
LU91609C LU91609I2 (fr) 1990-05-31 2009-09-24 Sérotype pneumococcique polysaccharidique 1,4,5,6B,7F,9V,14 et 23F conjugé aux protéines D (dérivé du non-typable Haemophilus influenzae); Sérotype pneumococcique polysaccaridique 18C conjugé au transporteur anatoxine tétanique protéines; Sérotype pneumococcique polysaccharidique 19F conjugé au transporteur anatoxine diphtérique protéines (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)

Family Applications After (1)

Application Number Title Priority Date Filing Date
LU91609C LU91609I2 (fr) 1990-05-31 2009-09-24 Sérotype pneumococcique polysaccharidique 1,4,5,6B,7F,9V,14 et 23F conjugé aux protéines D (dérivé du non-typable Haemophilus influenzae); Sérotype pneumococcique polysaccaridique 18C conjugé au transporteur anatoxine tétanique protéines; Sérotype pneumococcique polysaccharidique 19F conjugé au transporteur anatoxine diphtérique protéines (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)

Country Status (15)

Country Link
US (9) US5989828A (fr)
EP (1) EP0594610B1 (fr)
JP (1) JP3066072B2 (fr)
AT (1) ATE170531T1 (fr)
AU (1) AU650011B2 (fr)
CA (1) CA2083172C (fr)
DE (3) DE122009000060I1 (fr)
DK (1) DK0594610T3 (fr)
ES (1) ES2119776T3 (fr)
FI (1) FI109029B (fr)
LU (2) LU91610I2 (fr)
NL (2) NL300409I2 (fr)
NO (4) NO309721B1 (fr)
SE (1) SE466259B (fr)
WO (1) WO1991018926A1 (fr)

Families Citing this family (294)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
SE9201331D0 (sv) * 1992-04-28 1992-04-28 Hightech Receptor C O Active Protein l och hybridproteiner daerav
US6153406A (en) * 1993-07-23 2000-11-28 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane protein P2 from Haemophilus influenzae type B
US20020055101A1 (en) 1995-09-11 2002-05-09 Michel G. Bergeron Specific and universal probes and amplification primers to rapidly detect and identify common bacterial pathogens and antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US6001564A (en) * 1994-09-12 1999-12-14 Infectio Diagnostic, Inc. Species specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
NZ306316A (en) * 1995-04-17 2001-06-29 Smithkline Beecham Biolog S use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen
US5994066A (en) * 1995-09-11 1999-11-30 Infectio Diagnostic, Inc. Species-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial pathogens and associated antibiotic resistance genes from clinical specimens for routine diagnosis in microbiology laboratories
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
US20030049636A1 (en) 1999-05-03 2003-03-13 Bergeron Michel G. Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
US20050033022A1 (en) * 1997-09-26 2005-02-10 Smithkline Beecham Biologicals Sa Fusion proteins comprising HIV-1 Tat and/or Nef proteins
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
TR200002284T2 (tr) 1998-02-05 2000-11-21 Smithkline Beecham Biologicals S.A. Mage ailesinden tümör ile ilgili tümör türevleri
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6531315B1 (en) 1998-03-18 2003-03-11 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6660838B1 (en) 1998-03-18 2003-12-09 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6706262B1 (en) 1998-03-18 2004-03-16 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6518256B1 (en) 1998-03-18 2003-02-11 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6482597B1 (en) 1999-12-17 2002-11-19 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6312695B1 (en) 1998-03-18 2001-11-06 Corixa Corporation Compounds and methods for therapy of lung cancer
US6426072B1 (en) 2000-08-02 2002-07-30 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7049063B2 (en) 1998-03-18 2006-05-23 Corixa Corporation Methods for diagnosis of lung cancer
US6821518B1 (en) 1998-03-18 2004-11-23 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US7579160B2 (en) 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US6342231B1 (en) 1998-07-01 2002-01-29 Akzo Nobel N.V. Haemophilus parasuis vaccine and diagnostic
JP2002522451A (ja) 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
TR200102500T2 (tr) 1998-12-08 2002-03-21 Corixa Corporation Chlamydia enfeksiyonunu tedavi etmek i‡in bileçikler.
US20020119158A1 (en) 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en) 1998-12-28 2003-06-17 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en) 1999-01-29 2007-04-03 Corika Corporation HER-2/neu fusion proteins
AU3158900A (en) * 1999-02-25 2000-09-14 Smithkline Beecham Biologicals (Sa) Immunogens comprising a peptide and a carrier derived from h.influenzae protein
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
HK1049848A1 (zh) 1999-04-02 2003-05-30 科里克萨有限公司 用於治療和診斷肺癌的化合物和方法
US20040040205A1 (en) * 2002-04-25 2004-03-04 Weder Donald E. Wrapper with decorative extension and method
CA2388461C (fr) 1999-09-28 2013-06-11 Infectio Diagnostic (I.D.I.) Inc. Genes tres bien conserves pour produire des sondes moleculaires et des amorces dans la detection des microorganismes
DE60143425D1 (de) 2000-02-23 2010-12-23 Smithkline Beecham Biolog Neue verbindungen
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
AU2001255596A1 (en) 2000-04-21 2001-11-07 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60139963D1 (de) 2000-06-20 2009-10-29 Corixa Corp Fusionsproteine aus mycobakterium tuberculosis
EP1961819A3 (fr) 2000-06-28 2008-11-12 Corixa Corporation Composition et procédés pour la thérapie et le diagnostic du cancer des poumons
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
OA12302A (en) 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
EP1317253A4 (fr) * 2000-07-28 2006-04-26 Univ Emory Composant biologique comprenant une membrane artificielle
US7229623B1 (en) 2000-08-03 2007-06-12 Corixa Corporation Her-2/neu fusion proteins
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0025171D0 (en) * 2000-10-13 2000-11-29 Smithkline Beecham Biolog Novel compounds
DK2266603T3 (da) 2000-10-18 2012-11-05 Glaxosmithkline Biolog Sa Tumorvacciner
GB0025998D0 (en) * 2000-10-24 2000-12-13 Smithkline Beecham Biolog Novel compounds
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US20040241638A1 (en) * 2001-04-30 2004-12-02 Joelle Thonnard Novel compounds
EP1515982A4 (fr) 2001-05-09 2005-10-26 Corixa Corp Methodes et compositions pour la therapie et le diagnostic du cancer de la prostate
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性ＩｇＥワクチン
DE60238864D1 (de) * 2001-11-07 2011-02-17 Mankind Corp Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption
CA2860702C (fr) 2001-12-17 2019-02-26 Corixa Corporation Compositions et procedes applicables a la therapie et au diagnostic pour la maladie intestinale inflammatoire
DK2011510T3 (da) 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
ES2556970T3 (es) 2003-01-06 2016-01-21 Corixa Corporation Ciertos compuestos de fosfato de aminoalquil glucosaminida y sus usos
DK1587537T3 (da) 2003-01-30 2012-07-16 Novartis Ag Injicerbare vacciner mod multiple meningococ-serogrupper
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
SI1670506T1 (sl) 2003-10-02 2013-03-29 Novartis Ag Tekoča cepiva proti multiplim meningokoknim seroskupinam
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP2005112827A (ja) * 2003-10-10 2005-04-28 National Institute Of Advanced Industrial & Technology 抗体アフィニティ担体
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP3203241A1 (fr) 2004-07-14 2017-08-09 The Regents of The University of California Biomarqueurs pour la détection précoce du cancer des ovaires
JP2008513406A (ja) 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
WO2006104890A2 (fr) 2005-03-31 2006-10-05 Glaxosmithkline Biologicals Sa Vaccins destines a lutter contre une infection a chlamydia
KR102378962B1 (ko) 2005-04-08 2022-03-28 와이어쓰 엘엘씨 다가 폐렴구균 다당류-단백질 접합체 조성물
EP1871411A4 (fr) 2005-04-18 2010-07-21 Novartis Vaccines & Diagnostic Procede pour exprimer un antigene de surface de virus de l'hepatite b afin de preparer un vaccin
KR20130110233A (ko) 2005-04-29 2013-10-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 결핵균 감염을 예방 또는 치료하기 위한 신규한 방법
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
CA2621023C (fr) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Vaccination multiple comprenant des meningocoques du serogroupe c
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
CN103251940A (zh) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
EP1981905B1 (fr) 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Vaccin contre chlamydia
SG10201600336RA (en) 2006-01-17 2016-02-26 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein e; pe)
WO2007087576A2 (fr) 2006-01-24 2007-08-02 The Uab Research Foundation Compositions et méthodes d’identification et de traitement de maladies infammatoires immuno-médiées
AU2007229449A1 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
EP1998802A2 (fr) 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Composition immunogène
EP2390360A1 (fr) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Procédé d'identification si un patient est réactif ou non à l'immunothérapie basé sur l'expression différentielle du gène IDO1
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
EP2586790A3 (fr) 2006-08-16 2013-08-14 Novartis AG Immunogènes d'Escherischia coli pathogènes des voies urinaires
EP2491947A3 (fr) 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccin
US8309096B2 (en) 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
DK2114993T3 (da) 2007-01-15 2012-10-22 Glaxosmithkline Biolog Sa Vaccine
BRPI0809926B8 (pt) 2007-04-04 2021-05-25 Infectious Disease Res Inst composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
WO2008135514A1 (fr) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccin
CA2687632C (fr) 2007-05-24 2013-01-15 Glaxosmithkline Biologicals S.A. Composition lyophilisee d'antigene
MX2009013949A (es) 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
EP3061462B1 (fr) 2007-07-02 2019-02-27 Etubics Corporation Procédés et compositions permettant de produire un vecteur d'adénovirus destiné à être utilisé avec des vaccinations multiples
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
CA2699856C (fr) 2007-09-17 2019-08-20 Oncomethylome Sciences Sa Detection de methylation amelioree
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulações de vacinais meningocócicas
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
WO2009104097A2 (fr) 2008-02-21 2009-08-27 Novartis Ag Polypeptides fhbp à méningocoques
EP2334311B1 (fr) * 2008-09-17 2021-03-10 Hunter Immunology Pty Ltd Vaccins contre haemophilus influenzae non typable et leurs utilisations
EP2326992B1 (fr) * 2008-09-19 2015-04-22 Schoeller Technocell GmbH & Co. KG Matériau d'enregistrement pour un procédé d'impression laser
WO2010042481A1 (fr) 2008-10-06 2010-04-15 University Of Chicago Compositions et procédés associés aux protéines bactériennes eap, emp, et/ou adsa
US11065323B2 (en) 2008-10-27 2021-07-20 Glaxosmithkline Biologicals Sa Purification method
PE20110891A1 (es) 2008-12-09 2011-12-23 Pfizer Vaccines Llc Vacuna de peptido ch3 de ige
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
EP2367568A2 (fr) 2008-12-17 2011-09-28 Novartis AG Vaccins méningococciques comprenant un récepteur de l'hémoglobine
US7876118B2 (en) 2009-02-05 2011-01-25 Advantest Corporation Test equipment
CA2755734A1 (fr) 2009-03-17 2010-09-23 Gaetan Otto Detection amelioree de l'expression de genes
CA2756522C (fr) 2009-03-24 2018-06-26 Novartis Ag Proteine de liaison du facteur h meningococcique utilisee comme adjuvant
AU2010227220B2 (en) 2009-03-24 2014-11-13 Glaxosmithkline Biologicals S.A. Combinations of meningococcal factor H binding protein and pneumococcal saccharide conjugates
PT3281947T (pt) 2009-04-03 2020-05-07 Univ Chicago Composições e métodos relacionados com variantes da proteína a (spa)
WO2010119343A2 (fr) 2009-04-14 2010-10-21 Novartis Ag Compositions pour l'immunisation contre staphylococcus aureus
BRPI1014494A2 (pt) 2009-04-30 2016-08-02 Coley Pharm Group Inc vacina pneumocócica e usos da mesma
WO2010132833A1 (fr) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Compositions vaccinales contre streptococcus et méthodes d'utilisation associées
IN2012DN00446A (fr) 2009-07-30 2015-05-15 Pfizer Vaccines Llc
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
PE20121544A1 (es) 2009-09-03 2012-12-02 Pfizer Vaccines Llc Vacuna de pcsk9
CA2773637A1 (fr) 2009-09-10 2011-03-17 Novartis Ag Vaccins combines contre les maladies des voies respiratoires
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
AU2010302344A1 (en) 2009-09-30 2012-04-26 Novartis Ag Expression of meningococcal fhbp polypeptides
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
MX345967B (es) 2009-10-30 2017-02-28 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
HRP20161608T1 (hr) 2010-01-27 2017-01-13 Glaxosmithkline Biologicals Sa Modificirani tuberkulozni antigeni
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
EP2555794A4 (fr) 2010-04-05 2014-01-15 Univ Chicago COMPOSITIONS ET PROCÉDÉS LIÉS AUX ANTICORPS DE LA PROTÉINE A (SpA) EN TANT QUE AMPLIFICATEUR DE LA RÉPONSE IMMUNITAIRE
EP2575868A1 (fr) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Vaccin peptidique ige ch3
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
EP2588120B1 (fr) 2010-07-02 2017-11-15 The University of Chicago Compositions et méthodes associées à des variants de protéine a (spa)
EP2614074A1 (fr) 2010-09-09 2013-07-17 The University of Chicago Procédés et compositions impliquant des antigènes staphylococciques protecteurs
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012057904A1 (fr) 2010-10-27 2012-05-03 Infectious Disease Research Institute Antigènes du mycobacterium tuberculosis et leurs combinaisons présentant une séroréactivité élevée
EA201390676A1 (ru) 2010-11-08 2013-11-29 Инфекшес Дизиз Рисерч Инститьют Вакцины, содержащие полипептиды неспецифической нуклеозидгидролазы и стерол 24-c-метилтрансферазы (smt), для лечения и диагностики лейшманиоза
WO2012072769A1 (fr) 2010-12-01 2012-06-07 Novartis Ag Epitopes rrgb de pneumocoque et combinaisons de variantes
WO2012085668A2 (fr) 2010-12-24 2012-06-28 Novartis Ag Composés
CA2822953C (fr) * 2011-01-26 2022-02-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Detection selective de haemophilus influenzae
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
US20140004142A1 (en) 2011-03-02 2014-01-02 Pfizer Inc. Pcsk9 vaccine
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
WO2012129483A1 (fr) 2011-03-24 2012-09-27 Novartis Ag Nanoémulsions adjuvantes avec des phospholipides
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
TW201302779A (zh) 2011-04-13 2013-01-16 Glaxosmithkline Biolog Sa 融合蛋白質及組合疫苗
WO2012170356A1 (fr) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions et procédés associés à la protéine p6 de l'haemophilus influenzae
EP2729178A1 (fr) 2011-07-08 2014-05-14 Novartis AG Procédé de ligature de la tyrosine
CN103717613A (zh) 2011-07-22 2014-04-09 葛兰素史密丝克莱恩生物有限公司 Prame纯化
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
GB201114919D0 (en) 2011-08-30 2011-10-12 Glaxosmithkline Biolog Sa Method
US9493517B2 (en) 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule
EP2592137A1 (fr) 2011-11-11 2013-05-15 Novartis AG Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
CA2862247A1 (fr) 2011-12-29 2013-07-04 Novartis Ag Combinaisons avec adjuvant de proteines meningococciques liant le facteur h
EP2822586A1 (fr) 2012-03-07 2015-01-14 Novartis AG Formulations contenant un adjuvant d'antigènes de streptococcus pneumoniae
CN104159603A (zh) 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
HRP20201127T1 (hr) 2012-04-26 2020-11-27 University Of Chicago Antigeni stafilokokne koagulaze i metode primjene istih
EP2852414B9 (fr) 2012-05-22 2020-12-09 GlaxoSmithKline Biologicals SA Conjugué de sérogroupe x de méningocoque
EP2666785A1 (fr) 2012-05-23 2013-11-27 Affiris AG Vaccins basés sur la protéine complément C5a
PT2879701T (pt) 2012-08-03 2024-02-12 Access To Advanced Health Inst Composições e métodos para o tratamento de uma infeção ativa por mycobacterium tuberculosis
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
EP2703483A1 (fr) 2012-08-29 2014-03-05 Affiris AG Vaccin à base de PCSK9
BR112015005056A2 (pt) 2012-09-06 2017-11-21 Novartis Ag vacinas de combinação com sorogrupo b meningococcus e d/t/p
CA2896552A1 (fr) 2012-10-03 2014-04-10 Novartis Ag Compositions immunogenes
JP6440619B2 (ja) 2012-10-12 2018-12-19 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 混合ワクチン用の架橋されていない無細胞百日咳抗原
SMT201800011T1 (it) 2012-11-30 2018-05-02 Glaxosmithkline Biologicals Sa Antigeni e combinazioni di antigeni di pseudomonas
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
US9909114B2 (en) 2013-03-28 2018-03-06 Infectious Disease Research Institute Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
EP4098276A1 (fr) 2013-09-08 2022-12-07 Pfizer Inc. Compositions utilisables contre neisseria meningitidis et procédés associés
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
JP6612260B2 (ja) 2014-01-21 2019-11-27 ファイザー・インク 肺炎連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅ）莢膜多糖およびそのコンジュゲート
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MX371453B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
CA3206112A1 (fr) 2014-01-21 2015-07-30 Pfizer Inc. Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues et leurs utilisations
ES2930318T3 (es) 2014-02-14 2022-12-09 Pfizer Conjugados glucoproteicos inmunogénicos
TW201620927A (zh) 2014-02-24 2016-06-16 葛蘭素史密斯克藍生物品公司 Ｕｓｐａ２蛋白質構築體及其用途
AU2015222121B2 (en) 2014-02-28 2018-01-18 Glaxosmithkline Biologicals Sa Modified meningococcal fHbp polypeptides
EP3229833A1 (fr) 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Procédé de traitement
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
WO2016154010A1 (fr) 2015-03-20 2016-09-29 Makidon Paul Compositions immunogènes pour une utilisation en vaccination contre les bordetella
EP3325008B1 (fr) 2015-07-21 2025-09-10 Pfizer Inc. Compositions immunogènes contenant des antigènes saccharidiques capsulaires conjugués, kits comprenant ces compositions et leurs utilisations
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (fr) 2015-11-20 2017-05-26 Pfizer Inc. Compositions immunogènes destinées à être utilisées dans des vaccins pneumococciques
NZ742663A (en) 2015-12-04 2023-02-24 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2017175082A1 (fr) 2016-04-05 2017-10-12 Gsk Vaccines S.R.L. Compositions immunogènes
EP3458088A2 (fr) 2016-05-21 2019-03-27 Infectious Disease Research Institute Compositions et méthodes de traitement de la tuberculose secondaire et des infections à mycobacterium non tuberculeuses
EP3269385A1 (fr) 2016-07-12 2018-01-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugués de polysaccharide-protéine pneumococcique
WO2017220753A1 (fr) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition de conjugué polysaccharide pneumococcique-protéine
CA3035320A1 (fr) 2016-09-02 2018-03-08 Glaxosmithkline Biologicals Sa Vaccins contre neisseria gonorrhoeae
US20210108002A1 (en) 2016-12-06 2021-04-15 Glaxosmithkline Biologicals Sa Purification Process For Capsular Polysaccharide
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
US11413344B2 (en) 2017-01-20 2022-08-16 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CN110225757A (zh) 2017-01-31 2019-09-10 默沙东公司 由肺炎链球菌血清型19f生产荚膜多糖蛋白缀合物的方法
CN110225764A (zh) 2017-01-31 2019-09-10 默沙东公司 制备多糖-蛋白缀合物的方法
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US20200054740A1 (en) 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
CA3057778A1 (fr) * 2017-03-31 2018-10-04 Glaxosmithkline Biologicals Sa Composition immunogene, utilisation et methode de traitement
WO2018178265A1 (fr) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Composition immunogène, utilisation et procédé de traitement
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
CA3072018A1 (fr) * 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Procedes d'amplification des reponses immunitaires
PL3678654T3 (pl) 2017-09-07 2024-12-16 Merck Sharp & Dohme Llc Polisacharydy pneumokokowe i ich zastosowanie w immunogennych koniugatach polisacharyd-białko nośnikowe
JP2021504424A (ja) 2017-12-01 2021-02-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
US20210177957A1 (en) 2017-12-06 2021-06-17 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3106291A1 (fr) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Procedes de preparation de polysaccharides seches
EP3833382A1 (fr) 2018-08-07 2021-06-16 GlaxoSmithKline Biologicals S.A. Processus et vaccins
EP3607967A1 (fr) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Polypeptides modifiés du méningocoque fhbp
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020109365A1 (fr) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Procédés de fabrication d'un adjuvant
EP3894431A2 (fr) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Protéines porteuses modifiées pour glycosylation à liaison o
CA3120922A1 (fr) 2018-12-12 2020-06-18 Pfizer Inc. Conjugues polysaccharide-proteine immunogenes a heteroantigenes multiples et leurs utilisations
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
EP3923982A1 (fr) 2019-02-11 2021-12-22 Pfizer Inc. Compositions de neisseria meningitidiset procédés associées
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en) 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
JP2022532142A (ja) 2019-05-10 2022-07-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム コンジュゲートの製造
BR112021022902A2 (pt) 2019-05-14 2022-01-25 Univ Chicago Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
BR112021024363A2 (pt) 2019-06-05 2022-03-22 Glaxosmithkline Biologicals Sa Purificação de saponina
MX2022001241A (es) 2019-07-31 2022-04-20 Sanofi Pasteur Inc Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
JP2022543264A (ja) 2019-08-05 2022-10-11 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロテインｄポリペプチドを含む組成物を調製するプロセス
EP4010014A1 (fr) 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Composition immunogène
WO2021059181A1 (fr) 2019-09-27 2021-04-01 Pfizer Inc. Compositions de neisseria meningitidis et méthodes associées
CA3159573A1 (fr) 2019-11-01 2021-05-06 Pfizer Inc. Compositions d'escherichia coli et methodes associees
WO2021099982A1 (fr) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage et administration d'un vaccin à base de glycoconjugué de saccharide bactérien
CN115362177A (zh) 2020-02-21 2022-11-18 辉瑞公司 糖类的纯化
AU2021223184C1 (en) 2020-02-23 2025-02-27 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2021250626A2 (fr) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Système d'étiquette-ancrage
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
EP4232593A1 (fr) 2020-10-22 2023-08-30 Pfizer Inc. Procédés de purification de polysaccharides bactériens
US12138302B2 (en) 2020-10-27 2024-11-12 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021368151B2 (en) 2020-10-27 2024-09-05 Pfizer Inc. Escherichia coli compositions and methods thereof
AU2021373358B2 (en) 2020-11-04 2026-01-08 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US20230405137A1 (en) 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US12357681B2 (en) 2020-12-23 2025-07-15 Pfizer Inc. E. coli FimH mutants and uses thereof
TW202245835A (zh) 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
EP4294433A1 (fr) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Composition immunogène, utilisation et procédés
CA3218544A1 (fr) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination contre des infections bacteriennes et a betacoronavirus
WO2022234416A1 (fr) 2021-05-03 2022-11-10 Pfizer Inc. Vaccination contre des infections à pneumocoque et à covid-19
CA3221074A1 (fr) 2021-05-28 2022-12-01 Pfizer Inc. Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues et leurs utilisations
JP2024521847A (ja) 2021-05-28 2024-06-04 ファイザー・インク コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
WO2023039223A1 (fr) 2021-09-09 2023-03-16 Affinivax, Inc. Vaccins antipneumococciques multivalents
CA3247998A1 (fr) 2022-01-13 2023-07-20 Pfizer Inc. Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2023161817A1 (fr) 2022-02-25 2023-08-31 Pfizer Inc. Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
CN119317445A (zh) 2022-05-11 2025-01-14 辉瑞公司 用于生产含有防腐剂的疫苗制剂的方法
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
EP4558170A1 (fr) 2022-07-19 2025-05-28 GlaxoSmithKline Biologicals S.A. Procédé continu de production de vaccin
WO2024084397A1 (fr) 2022-10-19 2024-04-25 Pfizer Inc. Vaccination contre infections à pneumocoques et à covid-19
WO2024110827A1 (fr) 2022-11-21 2024-05-30 Pfizer Inc. Procédés de préparation d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
JP2025537898A (ja) 2022-11-22 2025-11-20 ファイザー・インク コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
AU2023403045A1 (en) 2022-12-01 2025-06-12 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (fr) 2023-02-10 2024-08-15 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
KR20250163977A (ko) 2023-03-30 2025-11-21 화이자 인코포레이티드 접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
WO2024214016A1 (fr) 2023-04-14 2024-10-17 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2024224266A1 (fr) 2023-04-24 2024-10-31 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et utilisations associées
WO2024238731A1 (fr) 2023-05-18 2024-11-21 Merck Sharp & Dohme Llc Composés et formulations d'adjuvant utiles dans des vaccins pneumococciques
EP4713008A2 (fr) 2023-05-19 2026-03-25 GlaxoSmithKline Biologicals S.A. Procédés de déclenchement d'une réponse immunitaire contre une infection par le virus respiratoire syncycial et streptococcus pneumoniae
TW202527906A (zh) 2023-09-14 2025-07-16 美商輝瑞股份有限公司 包含經結合之肺炎鏈球菌莢膜醣抗原之佐劑化致免疫性組成物及其用途
AR134355A1 (es) 2023-11-16 2026-01-07 Merck Sharp & Dohme Llc Composiciones de vacuna conjugadas con péptidos y métodos para el tratamiento de la enfermedad de alzheimer
WO2025133971A1 (fr) 2023-12-23 2025-06-26 Pfizer Inc. Procédés améliorés de production de glycoconjugués de saccharides capsulaires de bactéries
WO2025186705A2 (fr) 2024-03-06 2025-09-12 Pfizer Inc. Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
WO2025191415A1 (fr) 2024-03-11 2025-09-18 Pfizer Inc. Compositions immunogènes comprenant des saccharides conjugués d'escherichia coli et leurs utilisations
WO2025193903A1 (fr) 2024-03-15 2025-09-18 Affinivax, Inc. Compositions de polysaccharide pneumococcique et leurs utilisations
WO2025219904A1 (fr) 2024-04-19 2025-10-23 Pfizer Inc. Procédés améliorés de production de glycoconjugués par amination réductrice dans un solvant aprotique
WO2025219908A2 (fr) 2024-04-19 2025-10-23 Pfizer Inc. Procédés de fermentation de milieux et de fermentation pour la production de polysaccharides dans une culture de cellules bactériennes
WO2025242657A1 (fr) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Blocs et agrégats de construction de lipopeptides

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800798A (en) * 1972-07-11 1974-04-02 A Winkler Hydrophobic catheter construction
DE2322533C2 (de) * 1972-11-06 1986-08-28 Pharmacia AB, Uppsala Verfahren zum Binden von Immunoglobulin und Hilfsmittel zur Durchführung des Verfahrens
SE451596B (sv) * 1983-06-22 1987-10-19 Excorim Kb Forfarande for utvinning av protein g
SE459503B (sv) * 1985-05-03 1989-07-10 Excorim Kommanditbolag Hybrid-dna-molekyl innefattande dna-sekvens som kodar foer protein g samt foerfarande foer framstaellning av protein g
SE459662B (sv) * 1986-03-21 1989-07-24 Pharmacia Ab Hybrid-dna-molekyl som kodar foer ett protein med samma igg specificitet som protein g, plasmid innehaallande densamma samt foerfarande foer framstaellning av proteinet
US5173294A (en) * 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
AU623353B2 (en) * 1987-12-10 1992-05-14 Board Of Regents, The University Of Texas System Methods and compositions for the production of haemophilus influenzae type b major outer membrane protein antigens
EP0338265B1 (fr) * 1988-04-19 1994-05-04 American Cyanamid Company Vaccin à base d'un conjugat de protéine de membrane externe et de polysaccharide de type B d'haemophilus influenzae
USRE37919E1 (en) 1989-05-12 2002-12-03 The General Hospital Corporation Recombinant DNA method for production of parathyroid hormone
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US6680057B1 (en) 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor

Also Published As

Publication number Publication date
NL300410I1 (nl) 2009-12-01
FI109029B (fi) 2002-05-15
AU650011B2 (en) 1994-06-09
US5989828A (en) 1999-11-23
NL300409I2 (nl) 2010-03-01
NO924507L (no) 1992-11-30
DE69130116D1 (de) 1998-10-08
NO2009022I1 (no) 2009-10-12
US7666621B2 (en) 2010-02-23
DK0594610T3 (da) 1998-11-02
US6025484A (en) 2000-02-15
DE122009000059I1 (de) 2010-04-29
NO20003716L (no) 1992-11-30
US20070071774A1 (en) 2007-03-29
NO2009021I1 (no) 2009-10-12
NO322330B1 (no) 2006-09-18
EP0594610B1 (fr) 1998-09-02
SE466259B (sv) 1992-01-20
US5858677A (en) 1999-01-12
WO1991018926A1 (fr) 1991-12-12
NO309721B1 (no) 2001-03-19
SE9001949L (sv) 1991-12-01
US7115271B1 (en) 2006-10-03
CA2083172A1 (fr) 1991-12-01
US6139846A (en) 2000-10-31
NO20003716D0 (no) 2000-07-20
DE122009000060I1 (de) 2011-12-01
JP3066072B2 (ja) 2000-07-17
JPH05507465A (ja) 1993-10-28
ES2119776T3 (es) 1998-10-16
AU7559391A (en) 1991-12-31
USRE41277E1 (en) 2010-04-27
NO924507D0 (no) 1992-11-24
US5888517A (en) 1999-03-30
ATE170531T1 (de) 1998-09-15
LU91609I2 (fr) 2009-11-24
FI925460A0 (fi) 1992-11-30
CA2083172C (fr) 2002-07-02
SE9001949D0 (sv) 1990-05-31
NL300409I1 (nl) 2009-12-01
FI925460L (fi) 1992-11-30
EP0594610A1 (fr) 1994-05-04
DE69130116T2 (de) 1999-02-18
US20100209905A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
LU91610I2 (fr) Protéine D et ses dérivés pharmaceutiquement acceptables (SYNFLORIX - Vaccin pneumococcique polysaccharidique conjugé (adsorbé)
Une et al. Roles of V antigen in promoting virulence and immunity in yersiniae.
CA1152000A (fr) Immunisation contre les caries dentaires a l'aide d'antigenes a base de glucosyltransferase
AU649950B2 (en) A method for isolating and purifying transferrin and lactoferrin receptor proteins from bacteria and the preparation of vaccines containing the same
US4442085A (en) Protection against dental caries
NO964413L (no) Gruppe A streptokokkisk polysakkarid, immunogene blandinger derav samt anvendelse derav
IE873510L (en) Oligosaccharides.
CA2217522A1 (fr) Molecule isolee d'acide nucleique de proteine b regulee par fe (frpb) et vaccin utilisant cette molecule
Smith et al. Antigenic relatedness of glucosyltransferase enzymes from Streptococcus mutans
US5276142A (en) Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
US4220584A (en) E. coli enterotoxin vaccine for veterinary and human use
Watson et al. Studies on Infection with Bacillus anthracis: V. The Isolation of an Inflammatory Factor from Crude Extracts of Lesions of B. anthracis Infection and Its Biological and Chemical Relationship to Glutamyl Polypeptide
HUP9801223A2 (hu) Eljárás specifikus antigénekre adott antitest válasz fokozására interleukin-10-zel
NZ216267A (en) Vaccine production by treatment of pertussis toxin with a carbodiimide
CA1192840A (fr) Vaccin combine realise a partir de haemophilus influenzae de type b et un compsant de la membrane externe du virus de la coqueluche
US3987164A (en) Method for prevention of pseudomonas aeruginosa infections
Keusch et al. [22] Shiga toxin: Production and purification
WO1993024000A1 (fr) Procedes d'obtention et de purification de proteines de surface pneumococciques sans cellules a partir de s. pneumoniae et leur utilisation
Johnson Characterization of group A streptococcal R-28 antigen purified by hydroxyapatite column chromatography
Yakushiji et al. Purification and immunochemical studies of type b carbohydrate antigen of oral Streptococcus milleri